BRD7
Overview
BRD7 (Bromodomain-containing protein 7) is a component of the PBAF (Polybromo-associated BAF) SWI/SNF chromatin-remodeling complex. As a core PBAF subunit, BRD7 loss has been implicated in tumor immune evasion through disruption of chromatin remodeling that normally facilitates antigen-presentation and immune-stimulatory gene expression programs.
Alterations observed in the corpus
- BRD7 cited as an essential PBAF-complex component whose loss (in mouse models) sensitizes tumor cells to T-cell-mediated killing, supporting a PBAF-wide immune-priming mechanism relevant to immunotherapy response in ccRCC PMID:29301960.
Cancer types (linked)
- CCRCC (clear cell renal cell carcinoma): BRD7, as a PBAF subunit alongside PBRM1 and ARID2, is implicated in the immune-transcriptional landscape that modulates anti-PD-(L)1 response PMID:29301960.
Co-occurrence and mutual exclusivity
- BRD7 loss phenotypically overlaps with PBRM1 and ARID2 loss within the PBAF complex; mouse model data suggest each PBAF component contributes to a shared immune-sensitization mechanism PMID:29301960.
Therapeutic relevance
- PBAF-complex disruption (including BRD7 loss) is proposed as a mechanism sensitizing tumors to T-cell killing and potentially predicting benefit from anti-PD-(L)1 immunotherapy; however, direct clinical evidence linking BRD7 status to ICI response has not yet been reported PMID:29301960.
Open questions
- Whether BRD7 alteration alone (independent of PBRM1) is a sufficient immunotherapy-response biomarker in ccRCC or other solid tumors remains untested clinically.
Sources
This page was processed by crosslinker on 2026-05-15.